Mazyar Shadman, MD, MPH, reviews updated EHA 2026 data on all-oral, fixed-duration sonrotoclax plus zanubrutinib in relapsed or refractory CLL/SLL, including patients with del(17p)/TP53, addressing efficacy, durability, and the absence of tumor lysis syndrome.
Mazyar Shadman, MD, MPH, reviews phase 1 CaDAnCe-101 data on the BTK degrader catadegbrutinib in relapsed or refractory Waldenström macroglobulinemia, explaining how protein degradation differs from BTK inhibition and contextualizing the response and durability results.
An expert discusses how comprehensive genomic profiling using both tissue and liquid samples has become essential for personalized cancer care, particularly in lung cancer, where dual testing strategies can identify actionable mutations, guide treatment selection, and monitor resistance to improve patient outcomes.
Panelists discuss how advancements in biomarker testing and targeted therapies, particularly trastuzumab deruxtecan, are reshaping treatment strategies for HER2-overexpressing non-small cell lung cancer.
A panel of experts from the Tisch Cancer Institute at Mount Sinai and the Icahn School of Medicine at Mount Sinai share insights on biomarker testing protocols and best practices, biomarkers found in non-small cell lung cancer, and current and emerging treatments. They also share strategies for managing adverse events and for providing supportive care for patients.
Ghayas C. Issa, MD, provides an overview of acute myeloid leukemia and discusses the evolving treatment landscape, with a focus on genetic targeted therapies for patients with relapsed/refractory disease.
Narjust Florez, MD, reviews treatment strategies for managing hepatotoxicity and brain metastases in patients with KRASG12C mutated NSCLC while considering key recent trial data.
Sara M. Tolaney, MD, MPH, a breast oncologist at Dana-Farber Cancer Institute, provides comprehensive insights on the evolving breast cancer treatment landscape.
James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss diagnosis, risk stratification, treatment options, and recent updates from ongoing trials in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), acute myeloid leukemia (AML), as well as allogeneic transplants.
André Goy, MD, and Andrew Ip, MD, discuss clinical trial data and the evolving treatment landscapes for mantle cell lymphoma and diffuse large B-cell lymphoma.
David O’Malley, MD, reviews endometrial carcinoma, discussing treatment standards, and emerging data presented at the 2023 SGO (Society of Gynecologic Oncology) Annual Meeting on Women’s Cancer.
Noa Biran, MD, and David Siegel, MD, have a detailed discussion on the evolving treatment landscape in relapsed/refractory multiple myeloma.
Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, have a detailed discussion about the evolving treatment landscape for triple-negative breast cancer.
Joshua Richter, MD, discusses the evolving treatment landscape in relapsed/refractory multiple myeloma.
Virginia Kaklamani, MD and Heather McArthur, MD discuss updates in HR+ breast cancer, with a focus on treatment options before and after progression, treatment selection, and emerging data.
Joyce O’Shaughnessy, MD discusses a modern approach to treating patients with early-stage HER2+ breast cancer, elaborating on the entire process from the initial determination of patient eligibility to monitoring in the curative setting.
Dr Rafael Fonseca presents an overview of recent updates in the treatment of multiple myeloma and discusses strategies for incorporating the evidence into clinical practice.
Sarah M. Tolaney, MD, MPH, discusses the range of treatment options for early-stage HER2+ breast cancer, including subcutaneous options and investigational therapies.
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.
This OncView program features content experts who share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.
Virginia Kaklamani, MD, DSc, provides a discussion on the frontline and maintenance therapies available for the management of early-stage HER2+ breast cancer.
A leading expert in lung cancer provides insights on recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.
Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.
Roy S. Herbst, MD, PhD, reviews currently available treatment options in immunotherapy in non-small-cell lung cancer and approaches to monitoring treatment response.
Part 1: Oliver Sartor, MD, gives an overview of the use of PARP inhibitors to treat metastatic castration-resistant prostate cancer.
Part 2: Alicia Morgans, MD, MPH, discuses the importance of PARP inhibitors in the treatment of metastatic prostate cancer, as well as castration-resistant prostate cancer.
John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.
Connie Batlevi, MD, PhD, explains the treatment options for relapsed/refractory follicular lymphoma and discusses a recent drug approval.